Roche calmed Tecentriq skeptics with the latest lung cancer analysis

-- Roche has faced criticism since the successful development of Tecentriq monotherapy for previously untreated non-small cell lung cancer, saying its diagnostic tests to identify patients may have affected results. This is not the case, according to a new analysis.
In Roche's Phase 3 Impower110 trial, which identified patients belonging to this group, tyconic (athyparone monoantigen) showed benefits for patients with high levels of the biomarker Parkinson's-L1, the researchers said in a presentation at the ESMO Immuno-Oncology Conference.
Host Roy Herbst said that "although the diagnostic "sensitivity and scoring algorithm are different", but the total survival rate and no progression survival rate results are always conducive to acetyl monoantigen."
In other words, regardless of "diagnostic analysis, the analysis shows similar overall survival outcomes..." Dana Grebosch, an analyst at SVB Learink, wrote in a note to clients.
In her view, "these results refute criticism of the Tykenrech-positive IMpower110 results ... It is driven by a more selective diagnostic analysis (SP142) and improves Tekenrech's competitiveness among the previously un treated Parkinson's-L1 high population."
Related: ESMO: Did Roche's new Deakin Ritchie data match Ketchida's "leadership and loyalty" in lung cancer?
Tecentriq said in September that it could extend the lives of these patients by 7.1 months, longer than chemotherapy, and it hopes to join Merck's Keytruda as a second member of the PD-1/L1 class to get approval for a single treatment for first-line lung cancer. Ketchuda's label instructs doctors to use a special test called 22C3 to screen patients with high levels of Parkinson's disease-L1 that can be treated.
The diagnosis showed that it selected more eligible patients with a high incidence of Parkinson's disease-L1 than others, suggesting to Greybosh and her colleagues that "doctors and pathologists will continue to favour and use 22C3." "
may give Merck some advantage because it's a test on their labels," she notes. But, she writes, "that is, the exploratory analysis gives the rationale for using the results to select Teknik."
At the same time, Roche "will continue to study which analysis is best suited to identify the clinical activity of ticanticon of different tumor types." "As our understanding develops, we will follow science and adapt our approach," a spokesman for swiss pharmaceutical company Genente said in an email.Related: Roche's Teknik wins on lung cancer But can it challenge Merck's Ketchuda?
However, even if DeKentik were licensed, Ketchuda would not be an easy drug to buy on the market, as it had been leading the way as early as October 2016.“ Oncologists who treat non-small cell lung cancer have strong leadership and loyalty to Kichuda," Grebosch wrote in a September report. （cyy123.com）